Literature DB >> 8479289

Reduction of calbindin-28k mRNA levels in Alzheimer as compared to Huntington hippocampus.

M K Sutherland1, L Wong, M J Somerville, L K Yoong, C Bergeron, M Parmentier, D R McLachlan.   

Abstract

Disturbances in calcium homeostasis have been observed to be associated with Alzheimer's and other neurodegenerative diseases. Increased total calcium levels and decreased levels of calcium binding proteins have been found in Alzheimer brain tissue. However, the mechanism behind these disturbances remain unknown. In situ hybridization with tritiated antisense RNA probes for the calcium binding proteins, calbindin-28k and calmodulin, was used to examine the expression of genes coding for these proteins in Alzheimer and Huntington brain tissues matched for age, agonal process and autopsy interval. mRNA levels for calbindin-28k were reduced by 35% in CA1 and CA2 regions of Alzheimer hippocampus, as compared to Huntington control. In contrast, calmodulin expression was unchanged in CA1 but reduced by 30% in CA2. mRNA expression of calbindin-28k and calmodulin in Alzheimer temporal cortex did not differ from control. There were no significant differences in calcium binding protein message levels in cerebellar Purkinje cells between Alzheimer and Huntington control. There was no correlation between calcium binding protein message levels and brain weight, autopsy interval, patient age or the extent of neurofibrillary degeneration. Instead, decreased calbindin-28k expression in Alzheimer-affected hippocampus was due to an increase in the percentage of neurons expressing lower message levels for these proteins.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8479289     DOI: 10.1016/0169-328x(93)90171-k

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  9 in total

1.  Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain.

Authors:  C J Heyser; E Masliah; A Samimi; I L Campbell; L H Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

2.  Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome.

Authors:  Jason Lockrow; Heather Boger; Heather Bimonte-Nelson; Ann-Charlotte Granholm
Journal:  Behav Brain Res       Date:  2010-04-02       Impact factor: 3.332

Review 3.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

4.  Sex differences in the cerebellum and frontal cortex: roles of estrogen receptor alpha and sex chromosome genes.

Authors:  Jean M Abel; Diane M Witt; Emilie F Rissman
Journal:  Neuroendocrinology       Date:  2011-02-16       Impact factor: 4.914

5.  Mapping of the colocalization of calretinin and tyrosine hydroxylase in the rat substantia nigra and ventral tegmental area.

Authors:  K R Isaacs; D M Jacobowitz
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

6.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

Authors:  Jason Lockrow; Annamalai Prakasam; Peng Huang; Heather Bimonte-Nelson; Kumar Sambamurti; Ann-Charlotte Granholm
Journal:  Exp Neurol       Date:  2008-12-10       Impact factor: 5.330

7.  Purinergic receptor-stimulated IP3-mediated Ca2+ release enhances neuroprotection by increasing astrocyte mitochondrial metabolism during aging.

Authors:  Jun Wu; J Deborah Holstein; Geeta Upadhyay; Da-Ting Lin; Stuart Conway; Elizabeth Muller; James D Lechleiter
Journal:  J Neurosci       Date:  2007-06-13       Impact factor: 6.167

8.  Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation.

Authors:  Marcus O W Grimm; Andrea Thiel; Anna A Lauer; Jakob Winkler; Johannes Lehmann; Liesa Regner; Christopher Nelke; Daniel Janitschke; Céline Benoist; Olga Streidenberger; Hannah Stötzel; Kristina Endres; Christian Herr; Christoph Beisswenger; Heike S Grimm; Robert Bals; Frank Lammert; Tobias Hartmann
Journal:  Int J Mol Sci       Date:  2017-12-19       Impact factor: 5.923

9.  Pretreatment with apoaequorin protects hippocampal CA1 neurons from oxygen-glucose deprivation.

Authors:  Julia A Detert; Erin L Adams; Jacob D Lescher; Jeri-Anne Lyons; James R Moyer
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.